Rime Bioinformatics

🎊 Happy 2025 🎇 Here's something about us.... 👨🔬 The origin of the company’s name is that “Rime” in English is synonymous with “hoarfrost.” It is based on the image of a thin layer of ice separating our clients from the information contained in their genomic data—one that we melt away. ❄️ 🧬 We are here to assist you on your bacteriophage and bioinformatics projects. #Phage #2025 #Bioinformatics

Yesterday, I was at the European Parliament for an inspiring discussion on “The Potential of #Bacteriophages in Fighting #AMR”. Grateful to see policymakers, researchers, and industry working together to tackle one of the greatest health challenges of our time!

Had a wonderful time with the French phage network at the Phages.fr conference this week ! I am excited to be heading next week to Boston and the Phage Futures Congress 2024, to meet the American community =)

[#HLTH] Last but not least! Discover our French companies coming together to showcase their latest innovations in digital health at HLTH Inc. US in Las Vegas, October 20-23.   Millet Innovation develops silicone gels with unique properties (pressure distribution, self-adhesion, skin tissue substitution, etc.) to compensate for certain deficiencies in the human body’s functions or to limit the factors that encourage the development of pathologies. Moona.Health's platform connects patients with qualified sleep therapists via telehealth. It ensures accessible, affordable, and high-quality sleep treatment, addressing the shortage of professionals, fragmented care, and long waitlists. Nova In Silico leverages advanced computational models to revolutionize the design and execution of clinical trials by digitally simulating efficacy on hundreds of thousands of virtual patients, each with a unique physiological makeup. Nova In Silico envisions a future where clinical trials are systematically run digitally first, enabling rapid and ethical advancements in medicine. Rime Bioinformatics specializes in high-performance bioinformatics analysis for bacteriophage research, ensuring the safety and efficacy of phage-based treatments. The company's mission is to support the development of phage therapies as a sustainable alternative to antibiotics. TraceX is a free, open-source eQMS designed for managing the end-to-end creation of medical devices. It is considered an all-in-one solution, as it includes everything needed for collaboration: a task manager, a virtual office, chat functionality, and a wiki. More information about the companies: https://lnkd.in/ev73qpeM Victor Vanbremeersch, Lucie Jolivet, solene grivolat, Julie Pitrat, Guillaume Abriat, Ludmilla Potiron, Nam-Hee LEE, Charlotte Avril, Karine MORYOUSSEF

🚨 Understanding Phage Resistance in Multi-Drug Resistant Enterococci 🚨 While certain phages can lyse some strains of multi-drug resistant (MDR) enterococci, other strains exhibit high levels of resistance, with the underlying mechanisms remaining poorly understood. 🔬 CRISPRi Screen Unveils Genetic Locus Linked to Phage Resistance 🔬 Researchers used a CRISPR interference (CRISPRi) screen to pinpoint a genetic locus on a mobilizable plasmid from Enterococcus faecalis associated with phage resistance. This locus encodes a putative serine recombinase followed by a Type IV restriction enzyme (TIV-RE), which was shown to restrict the replication of phage phi47 in vancomycin-resistant E. faecalis. Key discoveries include: - The identification of a genetic locus that contributes to phage resistance in MDR enterococci. - The role of TIV-RE in restricting phage replication, with phi47 evolving to overcome this defense by acquiring a missense mutation in a TIV-RE inhibitor protein. - The discovery that this inhibitor, named Type IV Restriction Inhibiting Factor A (tifA), binds to and inactivates diverse TIV-REs. 🔍 Implications for Phage Therapy and Resistance Mechanisms 🔍 These findings significantly advance the understanding of phage defense mechanisms in drug-resistant E. faecalis and provide valuable insight into how phages can evolve to overcome antiphage defense systems. This research could inform future strategies for phage therapy and combatting antibiotic resistance. #PhageTherapy #AntibioticResistance #Microbiology #CRISPRI #EnterococcusFaecalis #InfectiousDiseases #Biotechnology #PhageResearch https://lnkd.in/efwWWGR4

📢 Rime Bioinformatics is currently exhibiting at the Singapore Medical Fair until 13th September. 🇸🇬 Come and visit the booth no 2E01 under the pavilion of the French Chamber of Commerce in Singapore to learn more about Rime's gene annotation technology. 🔬 #MedicalFairAsia2024 #FrenchPavilion #bioinformatics #healthcareinnovation

🚨 Emerging Threat: Influenza Viruses and the Need for Innovative Antiviral Strategies 🚨 With the resurgence of influenza viruses as a significant global health threat, the research community emphasizes the critical need for new antiviral approaches beyond existing treatments. 🔬 t-6SLPhage: A Novel Influenza-A Virus Entry Blocker 🔬 In a recent study, researchers from South Korea have developed and evaluated a groundbreaking super-multivalent sialyllactosylated filamentous phage, termed t-6SLPhage, designed to serve as a potent entry blocker for Influenza A viruses. Key insights from the study include: A systematic exploration of structural variations in sialyllactosyl ligands, such as linkage type, valency, net charge, and spacer length, to optimize binding characteristics against target hemagglutinins and influenza viruses. The optimized SLPhage demonstrated exceptional inhibitory potency in in vitro infection inhibition assays. In vivo studies highlighted its efficacy as both a preventive and therapeutic intervention, even when administered 2 days post-infection under high-lethality conditions. A synergistic effect was observed when co-administered with oseltamivir, suggesting potential for combination therapies to enhance efficacy and combat resistance. 🔍 Implications for Future Therapeutics 🔍 These findings underscore the promise of sialylated filamentous bacteriophages as effective and safe influenza inhibitors. The adaptability of M13 phages for surface modifications also presents new opportunities for further engineering, aimed at enhancing therapeutic and preventive performance. #Influenza #AntiviralResearch #Virology #Biotechnology #PhageTherapy #DrugDevelopment #InfectiousDiseases #InnovativeTherapies

👨🔬 Rafael Guerra Lund thank you very much for your kind message. Here we are truly happy that this meeting and discussion was inspiring. Let's stay in contact and for sure, we will give you update on our news ! 🧬 Take care! #WorldAMRCongress #Bioinformatics #PhageTherapy

𝐓𝐡𝐞 𝐂𝐨𝐮𝐧𝐭𝐝𝐨𝐰𝐧 𝐢𝐬 𝐎𝐧!⏱ Just 1 week left until MEDICAL FAIR ASIA l MEDICAL FAIR THAILAND and Medical Manufacturing Asia!   Mark your calendars for 11-13 September and make sure to visit the French Pavilion at booth 2E03. The French Chamber of Commerce in Singapore (FCCS) is proud to present a selection of leading French companies at this prestigious international tradeshow.   We are excited to showcase:   CRYOPAL - Didactic - Dispositifs Médicaux - DMS Imaging - Lépine -MEDICAPTEURS - 𝐌𝐢𝐜𝐫𝐨𝐯𝐚l - 𝐌-𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞 - NatéoSanté - NORAKER - NOVAIR  - PARSYS Télémédecine - PRATICIMA - Rime Bioinformatics - Sidas World - TECHNOLOGIE MEDICALE - Teknimed - THT BIO-SCIENCE - Thuasne -TODA PHARMA !   📍 Marina Bay Sands, Sands Expo and Convention Center – Level B2, Singapore.   👉 To schedule B2B meetings with any of these innovative companies, please reach out to Stephanie Rungs at srungs@fccsingapore.com. #MedicalFairAsia2024 #MedicalManufacturingAsia2024 #FrenchPavilion #HealthcareInnovation #MedTech #MedicalDevices #SingaporeEvents #B2BMeetings #HealthTech #MedicalExpo #Innovation #TradeShow #SingaporeExpo

Today and tomorrow, we are participating to the 14th international bacteriophage conference here in Oxford. #PhgOx24